Dopamine D1R/DRD1 Antibody - BSA Free

Immunocytochemistry/ Immunofluorescence: Dopamine D1R/DRD1 Antibody [NBP2-16213] -

Dopamine Receptor D1 antibody [C2C3], C-term detects Dopamine Receptor D1 protein by immunofluorescent analysis.
Sample: Mock and transfected 293T cells were fixed in ice-cold MeOH for 5 min.
Green: Dopamine Receptor D1 stained by Dopamine Receptor D1 antibody [C2C3], C-term (NBP2-16213) diluted at 1:500.
Blue: Fluoroshield with DAPI.

Western Blot: Dopamine D1R/DRD1 Antibody - BSA Free [NBP2-16213] -

ICAM-1 reduces neurotransmitters expression that reflects in sensorimotor deficits and psychological stress after TBI. A, Immunofluorescent staining of NE (red) in the hippocampus area of WT and ICAM-1−/− mice after 10 and 20 psi FPI and merged with NeuN (green) and DAPI (blue). Scale bar: 20 μm (all panels). B, Quantification of NE staining in the hippocampus area of uninjured, 10 and 20 psi FPI WT and ICAM-1−/− mice using ImageJ software (n = 6/group). C–E, Western blot analysis of 5-HT1AR (C), DAD1R (D), NPY (E) and beta -actin in the tissue lysates of hippocampus of WT and ICAM-1−/− mice 48 h after 10 and 20 psi FPI. The bar graph with dot plots shows the quantification of 5-HT1AR (C), DAD1R (D), NPY (E) versus beta -actin (n = 6/group). F, Schematic presentation of the findings. All values are expressed as mean +/- SD two-way ANOVA followed by Bonferroni post hoc tests. Statistically significant ***p < 0.001 versus WT uninjured group; @@@p < 0.001 versus uninjured ICAM-1−/− group; #p < 0.05, ##p < 0.01, ###p < 0.001 versus WT corresponding injury groups; ns = non-significant. NE, norepinephrine; 5-HT1AR, 5-HT 1A receptor; DAD1R, DA D1 receptor; NPY, neuropeptide Y. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34135004), licensed under a CC-BY license. Not internally tested by Novus Biologicals.